上海口腔医学 ›› 2021, Vol. 30 ›› Issue (3): 263-267.doi: 10.19439/j.sjos.2021.03.008

• 论著 • 上一篇    下一篇

46例HIV/AIDS患者在高效抗逆转录病毒治疗第一年间口腔念珠菌感染及免疫状况动态变化

杜纤1,2,3, 熊辉2, 杨瑶3, 陈方淳1,2,3   

  1. 1.重庆医科大学附属口腔医院,重庆 401120;
    2.口腔疾病与生物医学重庆市重点实验室,重庆 401120;
    3.重庆市高校市级口腔生物医学工程重点实验室,重庆 401120
  • 收稿日期:2019-07-11 修回日期:2019-11-06 出版日期:2021-06-25 发布日期:2021-08-05
  • 通讯作者: 陈方淳,E-mail:xiaoxixi@hospital.cqmu.edu.cn
  • 作者简介:杜纤(1994-),女,在读硕士研究生,E-mail:500118@hospital.cqmu.edu.cn
  • 基金资助:
    重庆市卫生计生委医学科研重点项目(2016ZDXM020)

Dynamic changes of oral candida infection and immune status of 46 HIV/AIDS patients during the first year of highly active antiretroviral therapy

DU Xian1,2,3, XIONG Hui2, YANG Yao3, CHEN Fang-chun1,2,3   

  1. 1. Stomatological Hospital of Chongqing Medical University. Chongqing 401120;
    2. Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences. Chongqing 401120;
    3. Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education. Chongqing 401120, China
  • Received:2019-07-11 Revised:2019-11-06 Online:2021-06-25 Published:2021-08-05

摘要: 目的: 监测HIV/AIDS患者在高效抗逆转录病毒治疗(HAART)第一年间口腔念珠菌感染及免疫状态变化,并探讨其间的关系。方法: 随访46例HIV/AIDS患者,在HAART基线、治疗后3、6、12个月检测患者CD4+T淋巴细胞计数,对患者进行口腔检查并记录口腔念珠菌病发生情况,采集患者口腔含漱液,使用沙保罗琼脂培养基和CHROMagar念珠菌显色培养基进行培养及鉴定。采用SPSS 25.0软件包对数据进行统计学分析。结果: HIV/AIDS患者在治疗后3、6、12个月,CD4+T淋巴细胞计数分别为(327.91±138.82)、(329.65±142.66)和(319.98±97.90)个/mm3,显著高于基线值的(263.39±126.01)个/mm3P<0.05);治疗后3、6、12个月,口腔念珠菌病患病率分别为26.09%、21.74%和23.91%,显著低于基线值的52.17%(P<0.05);CD4+T淋巴细胞计数<200个/mm3的患者,口腔念珠菌病患病率显著高于CD4+T淋巴细胞计数≥200个/mm3的患者(P<0.05)。结论: HAART能升高患者CD4+T淋巴细胞计数,使患者免疫得到重建,降低口腔念珠菌病发生率;但CD4+T淋巴细胞计数<200个/mm3的患者,口腔念珠菌病患病率明显增加。

关键词: HIV, AIDS, 高效抗逆转录病毒治疗, 口腔念珠菌, 免疫状态

Abstract: PURPOSE: To monitor oral candida infection and immune status of HIV/AIDS patients during the first year of highly active antiretroviral therapy (HAART), and to explore the relationship between oral candida infection and immune status. METHODS: A total of 46 HIV/AIDS patients were followed up. At baseline, 3, 6 and 12 months after HAART, CD4+T lymphocytes were measured, oral examinations of patients were carried out and the occurrence of oral candidiasis was recorded. Oral rinses were collected, and Sabourd's dextrose agar and CHROMagar candida medium were used to culture and identify oral candida. Statistical analysis was performed by SPSS 25.0 software package. RESULTS: The counts of CD4+T lymphocytes in HIV/AIDS patients at 3, 6 and 12 months after HAART were (327.91±138.82), (329.65±142.66) and (319.98±97.90) cells/mm3, respectively, which were significantly higher than CD4+T lymphocytes(263.39±126.01) at baseline(P<0.05). The prevalence of oral candidiasis at 3, 6 and 12 months after HAART was 26.09%, 21.74% and 23.91%, respectively, which was significantly lower than that(52.17%) at baseline(P<0.05). The prevalence of oral candidiasis in patients with CD4+T lymphocyte <200 cells/mm3 was significantly higher than that in patients with CD4+T lymphocyte ≥200 cells/mm3P<0.05). CONCLUSIONS: HAART can increase CD4+T lymphocytes, reconstruct the immunity of patients and reduce the incidence of oral candidiasis, but the incidence of oral candidiasis significantly increased in patients with CD4+T lymphocyte <200 cells/mm3.

Key words: HIV, AIDS, Highly active antiretroviral therapy, Oral candida, Immune status

中图分类号: